Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials

Digestive and Liver Disease

Volumn 47, Issue 5, 2015, Pages 356-364

  Lopez, Anthony ^a   Ford, Alexander C ^b,c   Colombel, Jean Frédéric ^d   Reinisch, Walter ^e   Sandborn, William J ^f   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adalimumab; Golimumab; Infliximab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CORTICOSTEROID; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CAUSE OF DEATH; COLITIS; COLON RESECTION; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; HEART FAILURE; HOSPITALIZATION; HUMAN; INFECTION RISK; MALNUTRITION; META ANALYSIS; MILIARY TUBERCULOSIS; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; SEPSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; DRUG EFFECTS; INTESTINE MUCOSA; PATHOLOGY; STATISTICS AND NUMERICAL DATA;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; COLECTOMY; COLITIS, ULCERATIVE; HOSPITALIZATION; HUMANS; INFLIXIMAB; INTESTINAL MUCOSA; PLACEBOS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928826972     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.01.148     Document Type: Article

References (35)

1. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
2. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
3. Williet N., Pillot C., Oussalah A., et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflammatory Bowel Diseases 2012, 18:1641-1646.
4. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
5. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
6. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
7. Sandborn W.J., Feagan B.G., Marano C.W., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:85-95.
8. Sandborn W.J., Feagan B.G., Marano C.W., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe active ulcerative colitis. Gastroenterology 2014, 146:96-109.
9. Filippi J., Allen P.B., Hebuterne X., et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Current Drug Targets 2011, 12:1440-1447.
10. Stidham R.W., Lee T.C., Higgins P.D., et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2014, 39:660-671.
11. Danese S., Fiorino G., Peyrin-Biroulet L., et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Annals of Internal Medicine 2014, 160:704-711.
12. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions, Version 5.1.0. Cochrane book series 2011.
13. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996, 17:1-12.
14. Demets D.L. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987, 6:341-350.
15. Simonian D. Control Clinical trials 1986.
16. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21:1539-1558.
17. Altman D.G. Confidence intervals for the number needed to treat. British Medical Journal 1998, 317:1309-1312.
18. Panccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine, or infliximab+azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology 2011, 140(Suppl. 1):S134.
19. Makarchuk P.A. Infliximab monotherapy or infliximab in combination with methotrexate and mucosal healing in patient with ulcerative colitis. Gut 2009, 58(Suppl. 2):A323.
20. Armuzzi A., De Pascalis B., Lupascu A., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. European Review for Medical and Pharmacological Sciences 2004, 8:231-233.
21. Sambuelli A.M., Gil A.H., Negreira S.M., et al. Infliximab (IFX) is an efficient rescue therapy in acute corticosteroid resistant ulcerative colitis (UC). Gut 2011, 60(Suppl. 3):A49.
22. Laharie D., Bourreille A., Branche J., et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012, 380:1909-1915.
23. Ochsenkuhn T., Sackmann M., Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. European Journal of Gastroenterology and Hepatology 2004, 16:1167-1171.
24. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
25. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflammatory Bowel Diseases 2001, 7:83-88.
26. Feagan B.G., Sandborn W.J., Lazar A., et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014, 146:110-118.
27. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. CDS Review 2006, CD005112.
28. Rahimi R., Nikfar S., Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Medical Science Monitor 2007, 13:PI13-PI18.
29. Gisbert J.P., Gonzalez-Lama Y., Mate J. Systematic review: infliximab therapy in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2007, 25:19-37.
30. Ford A.C., Sandborn W.J., Khan K.J., et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology 2011, 106:644-659.
31. Huang X., Lv B., Jin H.F., et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. European Journal of Clinical Pharmacology 2011, 67:759-766.
32. Lv R., Qiao W., Wu Z., et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLOS ONE 2014, 9:e86692.
33. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology 2008, 6:644-653.
34. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. American Journal of Gastroenterology 2012, 107:1409-1422.
35. Long M.D., Herfarth H.H., Pipkin C.A., et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2010, 8:268-274.